News & Updates

$BP-lowering meds up risk of fractures in older people$

BP-lowering meds up risk of fractures in older people

02 May 2024

Older people who are initiating blood pressure (BP)-lowering medications appear to be at heightened risk of fractures, especially those who have dementia, as shown in a retrospective cohort study.

BP-lowering meds up risk of fractures in older people

02 May 2024

Landiolol reduces heart rate in tachyarrhythmia, LV dysfunction

02 May 2024 by

Use of landiolol, a highly selective and short-acting beta-1 blocker, demonstrates adequate safety and efficacy in terms of heart rate control among patients suffering from atrial tachyarrhythmias (ATs) and left ventricular (LV) dysfunction, suggest the results of a meta-analysis presented at EHRA 2024.

Landiolol reduces heart rate in tachyarrhythmia, LV dysfunction

02 May 2024

Dostarlimab-chemo a new SoC for endometrial cancer?

02 May 2024 by

In the second interim analysis of part 1 of the phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial, dostarlimab plus carboplatin/paclitaxel (CP) chemotherapy delivered a significant survival benefit in women with primary advanced or recurrent endometrial cancer.

Dostarlimab-chemo a new SoC for endometrial cancer?

02 May 2024

Medroxyprogesterone acetate a viable option for preventing ovulation during IVF

02 May 2024

In women undergoing autologous in vitro fertilization (IVF) for fertility treatment, ovulatory suppression with medroxyprogesterone acetate proves effective, with cycle and reproductive outcomes similar to that with gonadotropin-releasing hormone (GnRH) antagonist and the advantage of being cheaper, according to a study.

Medroxyprogesterone acetate a viable option for preventing ovulation during IVF

02 May 2024

Oral lasofoxifene helps improve genitourinary syndrome of menopause

01 May 2024

Oral lasofoxifene at either 0.25 or 0.5 mg daily confers benefits on genitourinary syndrome of menopause, with pooled data from two phase III trials showing significant improvements in vaginal signs or symptoms while having a favourable safety profile.

Oral lasofoxifene helps improve genitourinary syndrome of menopause

01 May 2024

Antenatal corticosteroid exposure poses no major threat to infant neurodevelopment

30 Apr 2024

Children who were exposed antenatally to betamethasone as opposed to placebo are not necessarily at a disadvantage in terms of neurodevelopment outcomes, as shown in a follow-up to the Antenatal Late Preterm Steroids (ALPS) trial.

Antenatal corticosteroid exposure poses no major threat to infant neurodevelopment

30 Apr 2024

Anticoagulation of little benefit to patients with device-detected AF, multiple comorbidities

30 Apr 2024 by

Giving oral anticoagulants to patients with device-detected atrial fibrillation (AF) and multiple comorbidities does not necessarily help lower the rate of cardiovascular events, according to a subgroup analysis of the NOAH-AFNET 6 trial.

Anticoagulation of little benefit to patients with device-detected AF, multiple comorbidities

30 Apr 2024

Long-term lecanemab reduces cognitive decline in early AD

30 Apr 2024 by

Treatment with lecanemab continue to provide benefits to patients with early Alzheimer’s disease (AD) through 24 months, according to the results of the ongoing open-label extension study of Clarity AD. Those who have been treated much later also show disease improvements.

Long-term lecanemab reduces cognitive decline in early AD

30 Apr 2024

Diltiazem carries increased risk of serious bleeding in certain AF patients

30 Apr 2024

The use of diltiazem, especially at doses exceeding 120 mg/d, appears to contribute to a heightened risk of serious bleeding compared with metoprolol in patients with atrial fibrillation (AF) who are receiving oral anticoagulant therapy, according to a retrospective cohort study.

Diltiazem carries increased risk of serious bleeding in certain AF patients

30 Apr 2024

CSR cuts angina episodes in patients with no further antianginal options

30 Apr 2024 by

In the placebo-controlled ORBITA-COSMIC* trial, an implantable coronary sinus reducer (CSR) does not increase transmural myocardial perfusion, but it reduces the frequency of angina and improves quality of life (QoL) in patients with no further antianginal options.

CSR cuts angina episodes in patients with no further antianginal options

30 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

BP-lowering meds up risk of fractures in older people

BP-lowering meds up risk of fractures in older people

Landiolol reduces heart rate in tachyarrhythmia, LV dysfunction

Landiolol reduces heart rate in tachyarrhythmia, LV dysfunction

Dostarlimab-chemo a new SoC for endometrial cancer?

Dostarlimab-chemo a new SoC for endometrial cancer?

Medroxyprogesterone acetate a viable option for preventing ovulation during IVF

Medroxyprogesterone acetate a viable option for preventing ovulation during IVF

Oral lasofoxifene helps improve genitourinary syndrome of menopause

Oral lasofoxifene helps improve genitourinary syndrome of menopause

Antenatal corticosteroid exposure poses no major threat to infant neurodevelopment

Antenatal corticosteroid exposure poses no major threat to infant neurodevelopment

Anticoagulation of little benefit to patients with device-detected AF, multiple comorbidities

Anticoagulation of little benefit to patients with device-detected AF, multiple comorbidities

Long-term lecanemab reduces cognitive decline in early AD

Long-term lecanemab reduces cognitive decline in early AD

Diltiazem carries increased risk of serious bleeding in certain AF patients

Diltiazem carries increased risk of serious bleeding in certain AF patients

CSR cuts angina episodes in patients with no further antianginal options

CSR cuts angina episodes in patients with no further antianginal options